RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Torii Pharmaceutical Co Stock

Torii Pharmaceutical Co P/E 2024

Torii Pharmaceutical Co P/E

21.67

Ticker

4551.T

ISIN

JP3635800000

WKN

887536

As of Aug 14, 2024, Torii Pharmaceutical Co's P/E ratio was 21.67, a -6.88% change from the 23.27 P/E ratio recorded in the previous year.

The Torii Pharmaceutical Co P/E history

Torii Pharmaceutical Co Aktienanalyse

What does Torii Pharmaceutical Co do?

Torii Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1921. The company is headquartered in Tokyo and employs over 1,200 employees. Torii specializes in the development and manufacturing of medicines for the treatment of diseases such as diabetes, cancer, kidney and liver diseases, as well as allergic diseases and mental disorders. The business model of Torii is based on developing and manufacturing innovative medicines that have a high benefit for patients. To achieve this, the company invests a large portion of its revenue in research and development of new drugs. The goal is to improve both the quality of life of patients and support society by creating new healing opportunities. Torii is divided into two business segments: Pharma and Nutraceuticals. In the Pharma segment, the company produces prescription drugs that are primarily sold in Japanese hospitals and clinics. On the other hand, the Nutraceutical division offers products that are sold without a prescription and focus on dietary supplements and health-promoting products. Torii has a wide range of products, ranging from various medications to dietary supplements and functional foods. One of Torii's most well-known products is an antidiabetic called "Trelagliptin". The medication is used to treat type 2 diabetes and is the best-selling diabetes medication in Japan. Another important product from Torii is "UFT™", a chemotherapy treatment for cancer. UFT™ is particularly effective in treating stomach, colon, and lung cancer. Another significant medication is "Micardis™", a blood pressure-lowering medication. The medication lowers blood pressure without unwanted side effects and is also available in Europe and the United States. In the Nutraceutical division, Torii offers various products such as vitamins, minerals, dietary supplements, functional foods, and beverages. One highlight is "Real Gold Three", a dietary supplement that contains eight valuable herbs and focuses on improving the immune system. The product is sold in both Japan and China. In recent years, the company has established strategic partnerships with various other companies to promote innovation and accelerate growth. In 2019, the company signed a collaboration agreement with the Vietnamese division of the British pharmaceutical giant GlaxoSmithKline (GSK). The goal of the collaboration is to strengthen the distribution of GSK products in the Vietnamese market. Torii sees itself not only as a pharmaceutical company but also as part of society. The company actively supports social projects and corporate social responsibility (CSR). For example, Torii supports the "Operation Smile" program, which aims to help children with cleft lips and palates. Overall, Torii is an important player in the Japanese pharmaceutical market specializing in research, development, and marketing of innovative medicines. The company has a broad portfolio and has expanded its product range in recent years with various high-quality products. With its partnerships and social initiatives, Torii demonstrates that it is not only a commercial company but also makes an important contribution to society and the health of people. Torii Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Torii Pharmaceutical Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Torii Pharmaceutical Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Torii Pharmaceutical Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Torii Pharmaceutical Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Torii Pharmaceutical Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Torii Pharmaceutical Co stock

What is the price-to-earnings ratio of Torii Pharmaceutical Co?

The price-earnings ratio of Torii Pharmaceutical Co is currently 21.67.

How has the price-earnings ratio of Torii Pharmaceutical Co changed compared to last year?

The price-to-earnings ratio of Torii Pharmaceutical Co has increased by -6.88% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Torii Pharmaceutical Co high compared to other companies?

Yes, the price-to-earnings ratio of Torii Pharmaceutical Co is high compared to other companies.

How does an increase in the price-earnings ratio of Torii Pharmaceutical Co affect the company?

An increase in the price-earnings ratio of Torii Pharmaceutical Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Torii Pharmaceutical Co affect the company?

A decrease in the price-earnings ratio of Torii Pharmaceutical Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Torii Pharmaceutical Co?

Some factors that influence the price-earnings ratio of Torii Pharmaceutical Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Torii Pharmaceutical Co pay?

Over the past 12 months, Torii Pharmaceutical Co paid a dividend of 120 JPY . This corresponds to a dividend yield of about 3.43 %. For the coming 12 months, Torii Pharmaceutical Co is expected to pay a dividend of 121.66 JPY.

What is the dividend yield of Torii Pharmaceutical Co?

The current dividend yield of Torii Pharmaceutical Co is 3.43 %.

When does Torii Pharmaceutical Co pay dividends?

Torii Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Torii Pharmaceutical Co?

Torii Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Torii Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 121.66 JPY are expected. This corresponds to a dividend yield of 3.48 %.

In which sector is Torii Pharmaceutical Co located?

Torii Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Torii Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Torii Pharmaceutical Co from 3/1/2025 amounting to 60 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Torii Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Torii Pharmaceutical Co in the year 2023?

In the year 2023, Torii Pharmaceutical Co distributed 100 JPY as dividends.

In which currency does Torii Pharmaceutical Co pay out the dividend?

The dividends of Torii Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Torii Pharmaceutical Co

Our stock analysis for Torii Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torii Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.